Leading executives in Karessa Pharma AB acquire stock options in Karessa Pharma Holding AB
Karessa Pharma Holding AB announces today that the stock option program adopted at the Annual General Meeting on 29th of May 2017 has now been implemented. Of the total of 330,000 options in Karessa Incentive AB, 280,000 have been allocated to leading executives.Karessa Pharma Holding AB's wholly owned subsidiary, Karessa Incentive AB, has transferred 230,000 options to CEO Michael Brobjer and 50,000 to Chief technology officer Erik Mascher in Karessa Pharma Holding AB. The options were issued by a decision at Karessa Pharma Holding AB's Annual General Meeting 2017. Each options entitle